Press Releases

PCI Pharma Services Announces Global Expansion of Clinical Trial Services

PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, announced a significant milestone in its global clinical footprint with the creation of a new Clinical Center of Excellence (COE) in Western Europe at its Berlin...

Lonza’s Ibex Dedicate to Support the Commercial Manufacture of Kodiak’s KSI-301

We are committed to supporting Kodiak as they bring their highly innovative, sight-saving treatment option to patients with vision-threatening retinal diseases. Since 2014, we have been partnering with Kodiak to support the supply of KSI-301 drug substance for use...

Dalton Pharma Services Partners with Vido-InterVac to Combat Covid-19

Dalton Pharma Services, a leading North American pharmaceutical cGMP CDMO, is pleased to announce a partnership with the University of Saskatchewan’s Vaccine and Infectious Disease Organization–International Vaccine Centre (VIDO-InterVac), a global leader in human and animal infectious disease research...

Thermo Fisher Scientific and Lyell Immunopharma Form Cell Therapy Manufacturing Partnership

Thermo Fisher Scientific Inc., the world leader in serving science, and biotechnology company Lyell Immunopharma, are partnering to develop manufacturing processes designed to create more effective cell therapies to benefit cancer patients. The companies will work together to improve...

FUJIFILM Diosynth Biotechnologies Texas Facility to Support COVID-19 Vaccine Candidate Manufacturing

FUJIFILM Diosynth Biotechnologies, a world leading contract development and manufacturing organization (CDMO) for biologics, viral vaccines and gene therapies, announced that its College Station, Texas, site will support COVID-19 vaccine candidate manufacturing, as part of Operation Warp Speed, a...

Sterling Signs Deal to Produce Potential COVID-19 Drug Candidate for Moleculin

Global contract development and manufacturing organisation (CDMO), Sterling Pharma Solutions has signed an agreement with Moleculin Biotech, Inc., to support the company’s expanded development efforts for its potential COVID-19 treatment, WP1122. Moleculin is a clinical stage pharmaceutical company with a...

Cipla receives regulatory approval for launch of Ciplenza (Favipiravir 200 mg) in India to treat mild to moderate COVID-19

Cipla Limited announced that it has been granted regulatory approval by the Drug Controller General of India (DCGI) for the launch of Favipiravir in the country under the brand name Ciplenza. The accelerated approval for manufacturing and marketing of...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read